Parkinsons and Movement Disorders

Novel Insights and Therapeutics for Parkinson Disease

Submit Abstract Register Now

Parkinson’s disease is that the primary growth driver of the worldwide Parkinson’s disease therapeutics. According to the estimates of the World Health Organization, the worldwide prevalence of Parkinson’s disease was valued at over 10 million in 2012. The share of the world’s population above the age of 65 years can increase from 7-membered in 2000 to 16 PF in 2050. The therapeutics of Parkinson Disease includes designing a Clinical trial for parkinsonian disorders, Outcome of clinical trials in PSP, MSA and CBD, therapeutic options for mood, Cognition and Psychosis, Treatment of Parkinson patient with psychosis,  Rehabilitation therapies for Parkinson Disease, Medical and Surgical treatment, RNAi and antibody-based therapeutic approaches, therapies targeting autophagy in movement disorders, Isogenic human-induced pluripotent stem cells, Human embryonic stem cell-based therapies in Parkinson disease,  Novel proteinopathy based tracers for diagnosis, Therapeutic developments in the treatment of cognitive impairment,  Morphological and molecular basis of levodopa-induced dyskinesia’s, Electrophysiological, and their therapeutic implications.